Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
My Lists

Coda Biotherapeutics

329 Oyster Point Boulevard, 3rd Floor
So. San Francisco, CA 94408
Website Company Summary Management Team

CEO: Michael Narachi (8/31/2018)
Technology: Orion Keifer (8/31/2018)
Former Employees: Elizabeth Alcamo

Outside board: (May no longer be on the board) Mitchell H. Finer (MPM Capital Executive Partner) Todd Foley (MPM Capital) Tom Woiwode (Versant Ventures managing dir)

Business description: Coda Biotherapeutics seeks to provide relief to the millions of people living with intractable diseases through the use of innovative techniques in gene therapy. CODA Biotherapeutics’ revolutionary chemogenetic platform aims to control the activity of cells to treat disease. With chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable “switch” protein. Cells modified with the “switch” can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells. CODA’s engineered receptors will be able to modulate the activity of virtually any cell in which the receptor is ectopically expressed, making them suitable for the treatment of many disorders. CODA can further tailor the therapy to a particular disease by simply changing the viral capsid, DNA regulatory elements, and route of administration.

Rounds: 2
Recent Fundings: Nov 2019   Sep 2018
Capital raised: 34.0M
Last Round: 15.0M
Ownership: Private  
VCs include: MPM Capital Versant Ventures
Corporate investors: Novartis

Last Tweets


Last Mentions

Record updated: Nov 2019
Sector: Medical
Headcount: 11-25
Rounds: 2
Recent Fundings: Nov 2019   Sep 2018
Capital Raised: 34.0M
Last Round: 15.0M
Ownership: Private